Edgar Filing: Neuralstem, Inc. - Form 8-K

Neuralstem, Inc.		
Form 8-K		
February 22, 2017		
UNITED STATES SECURITIES AND EXCHANGE CO Washington, D.C. 20549	MMISSION	
Form 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the	Securities Exchange Act of 1934	
Date of Report	(Date of earliest event Reported): Febr	ruary 22, 2017
(Exact	Neuralstem, Inc.  Name of Registrant as Specified in C	harter)
Delaware	001-33672	52-2007292
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
20271 Goldenrod Lane, 2nd Floor, Maryland 20876		
(Address of Principal Executive Offi	ces) (Zip Code) <b>301-366-4960</b>	
(Regist	rant's telephone number, including are	ea code)
Check the appropriate box below if the the registrant under any of the following	e e	taneously satisfy the filing obligation of
[ Written communications pursuant to	Rule 425 under the Securities Act (17	7 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: Neuralstem, Inc. - Form 8-K

#### Item 8.01. Other Events.

On February 22, 2017, Neuralstem, Inc. (the "Company") announced that US Patent No. 9572807 was issued by the United States Patent and Trademark Office for NSI-189, the lead compound in the Company's neurogenic small molecule program in the development for the treatment of major depressive disorder. A copy of the press release is attached to this report as Exhibit 99.01.

### Item 9.01. Financial Statements and Exhibits.

Exhibit No.	<b>Description</b>
99.01	Press Release Dated February 22, 2017

## Edgar Filing: Neuralstem, Inc. - Form 8-K

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neuralstem, Inc.

Date: February 22, 2017

By: /s/ Richard Daly
Richard Daly

Chief Executive Officer

# INDEX OF EXHIBITS

Exhibit No.	Description
99.01	Press Release Dated February 22, 2017